XENE

Xenon Pharmaceut

• TipRanks·23h ago

  Xenon to Unveil Phase 3 Azetukalner Data and Pipeline Advances at 2026 AAN Meeting

• Reuters·1d ago

  Xenon highlights Phase 3 X-TOLE2 azetukalner data in focal onset seizures at AAN 2026

• Benzinga·1d ago

  Xenon To Highlight Late-Breaking Science Oral And Poster Presentation Of Topline Phase 3 X-TOLE2 Study Results For Azetukalner In FOS, And Poster Presentation Of Long-Term 48-Month Azetukalner Data From X-TOLE Open Label Extension Study

• TipRanks·03/30 11:30

  Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (INTS), IQVIA Holdings (IQV) and Xenon (XENE)

• NASDAQ·03/27 23:23

  Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know

• NASDAQ·03/27 02:17

  Xenon Pharmaceuticals (XENE) Price Target Increased by 41.64% to 80.01

• Seeking Alpha·03/19 18:37

  Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech

• Dow Jones·03/16 12:38

  Xenon Pharmaceuticals Price Target Cut to $63.00/Share From $64.00 by Wedbush

• Dow Jones·03/16 12:38

  Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush

• Benzinga·03/16 12:29

  Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $63

• TipRanks·03/16 12:10

  Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Protagonist Therapeutics (PTGX) and CG Oncology, Inc. (CGON)

• TipRanks·03/16 12:01

  Xenon Pharmaceuticals price target lowered to $63 from $64 at Wedbush

• Reuters·03/16 11:17

  XENON PHARMACEUTICALS INC <XENE.O>: WEDBUSH CUTS TARGET PRICE TO $63 FROM $64

• Reuters·03/16 10:59

  XENON PHARMACEUTICALS INC <XENE.O>: LEERINK PARTNERS RAISES TARGET PRICE TO $63 FROM $50

• TipRanks·03/16 02:15

  H.C. Wainwright Keeps Their Buy Rating on Xenon (XENE)